Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Oct 08, 2024
Episode
254
Soundcloud
Share
Anti Drug Conjugates represent a new way of treating thoracic, breast, and gastrointestinal cancers. Despite recent successes, many ADCs failed during clinical development due to excessive toxicities and unfavorable risk-benefit profiles. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses ADCs and how clinicians can manage some of these toxicities.
Guest
Benjamin Levy
MD
Thoracic Medical Oncologist and Clinical Director of Medical Oncology
Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Professor of Oncology at Johns Hopkins University School of Medicine
Paolo Tarantino
MD
Medical Oncologist
Dana-Farber Cancer Institute
